GTCM
ALDX icon

Gyon Technologies Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Gyon Technologies Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-51,161
Closed -$205K – 273
2021
Q4 		$205K Buy
+51,161
New +$390K 0.04% 511

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Gyon Technologies Capital Management's ALDX Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2022, closing a stake of 51,161 shares — an estimated $205K sold.

Gyon Technologies Capital Management first reported a position in ALDX in Q4 2021 and held it in 1 quarter. The position peaked at $205K in Q4 2021. 111 funds tracked by Wall St. Rank hold ALDX as of Q1 2022.

  • Gyon Technologies Capital Management reported no remaining Aldeyra Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 51,161 Aldeyra Therapeutics shares in Q1 2022, an estimated $205K.
  • Gyon Technologies Capital Management first reported a position in Aldeyra Therapeutics in Q4 2021 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Aldeyra Therapeutics position peaked at $205K in Q4 2021.
  • 111 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.